Antitope Ltd and Opsona announce successful Composite Human Antibody project

 

  • Antitope Ltd (Cambridge) have completed the successful generation of a humanized antibody designed to avoid clinical immunogenicity for Opsona Therapeutics (Dublin).

 

Dublin, Ireland - January 2009

Antitope Ltd., a leader in the generation of therapeutic human antibodies with reduced immunogenicity, and Opsona Therapeutics Ltd., a leader in the development of therapeutics for the treatment of autoimmune/inflammatory disease, today announced the completion of a successful collaboration for the generation of a therapeutic antibody designated OPN-305.

During the collaboration, Antitope applied its Composite Human Antibody technology to humanise a murine monoclonal antibody resulting in a humanized antibody with devoid of T cell epitopes and thus with a low risk of immunogenicity.

"We are delighted to have had the opportunity to work with such an innovative and progressive company as Opsona," said Matthew Baker Ph.D, Chief Executive Officer of Antitope." Our collaboration has demonstrated the success of our Composite Human Antibody technology and we are excited about the prospects for Opsona's therapeutic antibodies."

Opsona's CEO, Mark Heffernan PhD, explained that "it has been a very successful programme of research. Our collaboration has yielded high affinity and low immunogenic antibodies, exceeding the criteria we originally established".

About Antitope
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope's proprietary Composite Human Antibody technology provides a novel solution to the detection and removal of T cell epitopes in antibodies/proteins through proprietary humanisation and DeImmunisation technologies. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies.

For further information on Antitope visit http://www.antitope.co.uk/ or contact:
Dr Neil Butt
Business Development Director
Tel: +44 1223 496190
Email: info@antitope.co.uk

For further information on Opsona visit http://www.opsona.com/ or contact

Email info@opsona.com

For media queries please contact

Niamh Lyons  Tel + 353 1 6633602
or
Jonathan Birt  Tel + 44 20 72697205